Press release centre
Past Press Releases - Trophos SA
October 2, 2013 Trophos announces final patient completion of Phase II Proof-of-Concept study of TRO40303 in ... Trophos announces final patient completion of Phase II Proof-of-Concept study of TRO40303 in patients treated for acute myocardial infarction. More
October 11, 2012 Trophos program boosted by EUR 1 million grant for olesoxime in progressive Multiple Sclerosis Agence Nationale de la Recherche awards second grant to Trophos led consortium for Phase Ib/IIa clinical study More
July 23, 2012 Trophos appoints JSB Partners as global partnership advisor Life science advisor to advise Trophos on strategic partnerships for orphan disease and niche indication candidates. More
February 24, 2011 Trophos successfully completes phase 1 study for novel cardioprotective compound, TRO40303 Phase 2 Proof-of-Concept study in acute myocardial infarction planned for second half 2011 with MitoCare EU consortium. More
November 24, 2010 Trophos and MS-Repair partners present promising data on novel approach in multiple sclerosis Oral presentation at the Society for Neuroscience congress highlights novel compounds to promote axon repair and remyelination in multiple sclerosis More
November 22, 2010 Trophos and the MitoTarget Consortium demonstrate potential of modulating mitochondrial dysfunction Trophos and the MitoTarget Consortium demonstrate potential of modulating mitochondrial dysfunction in the treatment of neurodegenerative diseases More
March 17, 2010 Trophos completes patient enrolment in pivotal phase 3 efficacy study of olesoxime in ALS Trophos completes patient enrolment in pivotal phase 3 efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease). More
September 29, 2009 Trophos launches the new generation of its fast plate imaging instrument, the Plate RUNNER HD Trophos targets opportunities with instrument manufacturers and vendors for well-proven system that plugs market gap in fast high resolution imaging. More
June 5, 2008 Trophos completes enrolment of Phase II Clinical Trial of TRO19622 in painful peripheral ... Trophos completes enrolment of Phase II Clinical Trial of TRO19622 in painful peripheral diabetic neuropathy More
May 29, 2008 Trophos demonstrates analgesic activity of neuroprotective agent TRO19622 in preclinical models Trophos demonstrates analgesic activity of neuroprotective agent TRO19622 in preclinical models of painful peripheral neuropathy More
May 15, 2008 Trophos starts phase II clinical trial of TRO19622 in liver disease Neurodegenerative disease specialist enrolls European Phase II of lead molecule in patients with Nonalcoholic Steatohepatitis More
September 28, 2007 Trophos starts phase Ib clinical trial of TRO19622 in spinal muscular atrophy Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that the company has begun enrolling Spinal Muscular Atrophy patients in a Phase Ib clinical trial of its lead product, TRO19622. More
September 4, 2007 Trophos Closes EUR 8.5 Million in Series C Funding Proceeds to fund TRO19622 and TRO40303 to clinical proof of concept for neurological, ischemia-reperfusion injury and liver disease indications More
May 30, 2006 Trophos appoints Jacques Essinger as President of Supervisory Board Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurodegenerative diseases, announced today the appointment of Jacques Essinger, PhD, as President of its Supervisory Board. More |